{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-004873","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2025-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.640279+00:00","generated_at":"2026-05-27T22:15:20.943474+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"INM-901 shows statistically significant reduction in neuroinflammation in long-term Alzheimer's model","bullets":["INM-901 dose-dependently and significantly reduced pro-inflammatory cytokines TNF-α, IL-1β, and INF-γ.","High dose group showed statistically significant reduction in neurodegeneration biomarker NfL in plasma.","mRNA data showed reduction of neuroinflammatory genes GFAP, CD-33, TLR-2 in brain, supporting study results.","Company will complete analyses of receptor engagement, neuritogenesis, and neuroprotection in coming weeks."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-004873","json":"https://secwatch.observer/filing/0001213900-25-004873.json","markdown":"https://secwatch.observer/filing/0001213900-25-004873.md","text":"https://secwatch.observer/filing/0001213900-25-004873.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025004873/0001213900-25-004873-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025004873/ea0228190-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T22:15:20.943474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}